398 Results for "

ATP binding

" in MedChemExpress (MCE) Product Catalog:
Products (398)

398 Results for "ATP binding" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-130777A
Purity:  ≥94.0%
Synonyms: Adenylyl imidodiphosphate lithium hydrate
AMP-PNP (Adenylyl imidodiphosphate) lithium hydrate is a non-hydrolyzable ATP analog. AMP-PNP lithium hydrate binds to ATP binding sites competely but is not hydrolyzed by enzymes, providing stable experimental conditions for studying ATP-dependent processes. AMP-PNP lithium hydrate can also be used to study enzyme activity, kinase regulation, DNA/RNA metabolism, ion channel function, and protein complex assembly .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18010
CAS No.: 330786-25-9
Target:  

Btk BCRP

Research Areas:  

Inflammation/Immunology

PCI 29732 is a potent, orally active, reversible BTK inhibitor with Ki app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112299
CAS No.: 1661854-97-2
Purity:  99.81%
Synonyms: TAS6417; CLN-081
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13299
CAS No.: 1001917-37-8
Purity:  98.34%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13299A
CAS No.: 1283000-43-0
Purity:  99.86%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-W004500
CAS No.: 116-31-4
All-trans-retinal is an vitamin A metabolite in the retina, and is produced following photo-isomerization of the visual chromophore 11-cis-Retinal. All-trans-retinal is cleared from photoreceptors by ATP-binding cassette transporter (ABCA4) and all-trans-retinol dehydrogenase (RDH). All-trans-retinal induces Bax activation via DNA damage to mediate retinal cell apoptosis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-11079
CAS No.: 944261-79-4
Purity:  99.09%
A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100848
CAS No.: 1603845-32-4
Purity:  98.28%
Target:  

EGFR

Research Areas:  

Cancer

TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-106005
CAS No.: 1314883-11-8
Purity:  99.17%
Target:  

Parasite PI4K

Research Areas:  

Infection

MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kd app=0.3 µM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15466
CAS No.: 1007207-67-1
Purity:  99.01%
Synonyms: CH5132799
Target:  

PI3K Apoptosis mTOR Akt

Research Areas:  

Cancer

Izorlisib (CH5132799) is an orally active, selective Class I PI3K inhibitor with an IC50 value of 14 nM against PI3Kα. Izorlisib specifically inhibits Class I PI3K (particularly PI3Kα and its mutants) and blocks the PI3K/Akt/mTOR pathway; this leads to cell cycle arrest at the G1 phase and apoptosis without triggering feedback activation of Akt by competitively binding to the ATP-binding site of PI3K. Izorlisib can be used in research on cancers harboring PIK3CA mutations or PTEN loss (such as breast, ovarian, prostate, and endometrial cancers) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N5112A
CAS No.: 34539-65-6
Synonyms: Arnebin 1
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC50=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-106723A
CAS No.: 7414-56-4
Purity:  99.29%
Target:  

HSP

Research Areas:  

Cancer

AMP-PCP disodium is an ATP analogue and can bind to Hsp90 N-terminal domain with a Kd value of 3.8 μM. AMP-PCP disodium binding favors the formation of the active homodimer of Hsp90 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-157508
CAS No.: 3061959-30-3
Purity:  99.94%
Target:  

p97

Research Areas:  

Others

VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10261B
CAS No.: 439081-18-2
Purity:  99.98%
Synonyms: (E/Z)-BIBW 2992
Research Areas:  

Others Cancer

(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-17547
CAS No.: 1253584-84-7
Target:  

HSP

Research Areas:  

Cancer

NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC50 of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-127111
CAS No.: 2375840-87-0
Purity:  99.54%
Target:  

ATP Citrate Lyase

Research Areas:  

Cancer

NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0656A
CAS No.: 7562-61-0
(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer and anti-inflammatory activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P80772
Synonyms: p-pg; PGP; ABCB1; MDR1; PGY1; Multidrug resistance protein 1; ATP-binding cassette sub-family B member 1; P-glycoprotein 1; CD antigen CD243

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human

loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0248
CAS No.: 58316-41-9
Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-125017
CAS No.: 1440964-89-5
Purity:  98.88%
Synonyms: PLB-1001; CBT-101; Vebreltinib
Target:  

c-Met/HGFR

Research Areas:  

Cancer

Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .
loading...
    loading...